BriaCell Therapeutics Corp. (BCTXW)

0.3428 +0.0125 (+3.78%) At close: 04:00PM EDT

BriaCell Therapeutics Corp.

Bellevue Centre
Suite 300 235 -15th Street
West Vancouver, BC V7T 2X1
Canada
604 921 1810
https://briacell.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 16

Description

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Corporate governance

BriaCell Therapeutics Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.